GSK plc

GSK

40.830USD

-0.650-1.57%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

67 / 176

Overall Ranking

193 / 4724

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Hold

Current Rating

38.339

Target Price

-7.57%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 96.66%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 96.66%.

Fairly Valued

The company’s latest PE is 18.68, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 378.08M shares, increasing 1.48% quarter-over-quarter.

Held by Van Duyn Dodge & E. Morris Cox

Star Investor Van Duyn Dodge & E. Morris Cox holds 78.76M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.27.

The company's current financial score is 7.68, which is higher than the Pharmaceuticals industry's average of 6.80. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 9.46B, representing a year-over-year increase of 1.33%, while its net profit experienced a year-over-year increase of 54.12%.

Score

Industry at a Glance

Previous score

7.68

Change

0



Financials

7.83

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.11

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.64

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.09

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.74

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.80, which is higher than the Pharmaceuticals industry's average of 1.64. Its current P/E ratio is 18.26, which is 7.00% below the recent high of 19.54 and 3.05% above the recent low of 17.70.

Score

Industry at a Glance

Previous score

1.80

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 67/176

No Data

The company’s current earnings forecast score is 6.20, which is lower than the Pharmaceuticals industry's average of 7.96. The average price target for GSK plc is 37.35, with a high of 45.00 and a low of 33.51.

Score

Industry at a Glance

Previous score

6.20

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 9.28, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 41.40 and the support level at 37.58, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.01

Change

0.03

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.02. The latest institutional shareholding proportion is 18.54%, representing a quarter-over-quarter increase of 0.22%. The largest institutional shareholder is Van Duyn Dodge & E. Morris Cox, holding a total of 78.76M shares, representing 3.87% of shares outstanding, with 17.14% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Dodge & Cox

Star Investors

78.65M

+14.92%

Fidelity Management & Research Company LLC

50.60M

+15.61%

Fisher Investments

Star Investors

30.03M

+59.43%

PRIMECAP Management Company

Star Investors

25.71M

+1.77%

JTC Employer Solutions Trusteee Ltd

15.26M

-24.75%

Fidelity Institutional Asset Management

9.52M

+5.15%

T. Rowe Price International Ltd

7.72M

+2.05%

RBC Capital Markets Wealth Management

6.25M

+7.54%

State Street Global Advisors (US)

6.97M

-0.74%

Goldman Sachs Asset Management, L.P.

8.47M

-4.30%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 5.51, which is higher than the Pharmaceuticals industry's average of 3.51. The company's beta value is 0.53. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

GSK plc

GSK

6.13 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

7.69 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.55 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

7.31 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cardinal Health Inc

CAH

7.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.